Published on in Vol 26 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/50330, first published .
Weight Gain Prevention Outcomes From a Pragmatic Digital Health Intervention With Community Health Center Patients: Randomized Controlled Trial

Weight Gain Prevention Outcomes From a Pragmatic Digital Health Intervention With Community Health Center Patients: Randomized Controlled Trial

Weight Gain Prevention Outcomes From a Pragmatic Digital Health Intervention With Community Health Center Patients: Randomized Controlled Trial

Original Paper

1School of Nursing, Johns Hopkins University, Baltimore, MD, United States

2Department of Biostatistics & Bioinformatics, Duke University, Durham, NC, United States

3Duke Global Health Institute, Duke University, Durham, NC, United States

4Duke Digital Health Science Center, Duke University, Durham, NC, United States

5Department of Pediatrics, Duke University, Durham, NC, United States

6Duke-NUS Medical School Singapore, Duke Global Health Institute, Duke University, Durham, NC, United States

7Caraway, New York, NY, United States

8Medical Home Network, Chicago, IL, United States

9Piedmont Health Services, Inc, Chapel Hill, NC, United States

10Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

11Trinity College of Arts & Sciences, Duke University, Durham, NC, United States

Corresponding Author:

Miriam B Berger, MPH

Duke Digital Health Science Center

Duke University

417 Chapel Drive, Room 048

Campus Box 90086

Durham, NC, 27708

United States

Phone: 1 919 613 8398

Email: miriam.berger@duke.edu


Related ArticleThis is a corrected version. See correction statement in: https://www.jmir.org/2024/1/e60137

Background: The prevalence of obesity and its associated comorbidities continue to rise in the United States. Populations who are uninsured and from racial and ethnic minority groups continue to be disproportionately affected. These populations also experience fewer clinically meaningful outcomes in most weight loss trials. Weight gain prevention presents a useful strategy for individuals who experience barriers to weight loss. Given the often-limited weight management resources available to patients in primary care settings serving vulnerable patients, evaluating interventions with pragmatic designs may help inform the design of comprehensive obesity care delivered in primary care.

Objective: This study aims to evaluate the effectiveness of Balance, a 2-arm, 12-month pragmatic randomized controlled trial of a digital weight gain prevention intervention, delivered to patients receiving primary care within federally qualified community health centers.

Methods: Balance was a 2-arm, 12-month pragmatic randomized controlled trial of a digital weight gain prevention intervention delivered to individuals who had a BMI of 25-40 kg/m2, spoke English or Spanish, and were receiving primary care within a network of federally qualified community health centers in North Carolina. The Balance intervention was designed to encourage behavioral changes that result in a slight energy deficit. Intervention participants received tailored goal setting and tracking, skills training, self-monitoring, and responsive health coaching from registered dietitians. Weight was measured at regular primary care visits and documented in the electronic health record. We compared the percentage of ≤3% weight gain in each arm at 24 months after randomization—our primary outcome—using individual empirical best linear unbiased predictors from the linear mixed-effects model. We used individual empirical best linear unbiased predictors from participants with at least 1 electronic health record weight documented within a 6-month window centered on the 24-month time point.

Results: We randomized 443 participants, of which 223 (50.3%) participants were allocated to the intervention arm. At baseline, participants had a mean BMI of 32.6 kg/m2. Most participants were Latino or Hispanic (n=200, 45.1%) or non–Latino or Hispanic White (n=115, 26%). In total, 53% (n=235) of participants had at least 1 visit with weight measured in the primary time window. The intervention group had a higher proportion with ≤3% weight gain at 6 months (risk ratio=1.12, 95% CI 0.94-1.28; risk difference=9.5, 95% CI –4.5 to 16.4 percentage points). This difference attenuated to the null by 24 months (risk ratio=1.00, 95% CI 0.82-1.20; risk difference=0.2, 95% CI –12.1 to 11.0 percentage points).

Conclusions: In adults with overweight or obesity receiving primary care at a community health center, we did not find long-term evidence to support the dissemination of a digital health intervention for weight gain prevention.

Trial Registration: ClinicalTrials.gov NCT03003403; https://clinicaltrials.gov/study/NCT03003403

International Registered Report Identifier (IRRID): RR2-10.1186/s12889-019-6926-7

J Med Internet Res 2024;26:e50330

doi:10.2196/50330

Keywords



The prevalence of obesity and its associated comorbidities continue to rise in the United States, and populations who are uninsured and from racial and ethnic minority groups continue to be disproportionately affected [1-8]. These populations also experience fewer clinically meaningful outcomes in most weight loss trials, suggesting a need for alternative intervention approaches to contend with obesity and its associated clinical outcomes [9-11]. Weight gain prevention presents a useful—and guidelines-adherent—strategy for individuals who experience barriers to, or have less success with, weight loss. Compared with weight loss, weight gain prevention can be achieved at lower treatment intensity and is well suited for delivery using electronic health technologies, yielding the potential to reach large, high-risk populations at low costs [12].

We previously demonstrated the efficacy of weight gain prevention interventions in a population of Black female individuals in the community health center (CHC) setting [12,13]. The intervention focused on creating a slight energy deficit sufficient to offset weight gain using medium-intensity digital health strategies. While efficacious, there were concerns about the intervention’s suitability for implementation, as it required significant staff effort and used labor-intensive technologies for participant engagement. Given the often-limited weight management resources available to patients in primary care settings serving vulnerable patients, more frequently evaluating intervention with pragmatic designs may help inform the design of comprehensive obesity care delivered in primary care [14].

We report outcomes from Balance, a 2-arm, 12-month pragmatic randomized controlled trial of a digital weight gain prevention intervention delivered to patients receiving primary care within Piedmont Health Services Inc (Piedmont), a network of Federally Qualified Community Health Centers located in central North Carolina. We hypothesized that, compared with usual care, the intervention arm would have a greater proportion of participants with ≤3% weight gain at 24 months after randomization.


Study Design

Full details of the trial protocol, study population, Balance intervention, and recruitment processes have previously been published [14] and are summarized here. Balance participants were adults with overweight or obesity who received care at participating Piedmont CHCs. Participants were randomized to receive either (1) the 12-month Balance weight gain prevention intervention or (2) a healthy living usual care arm. There were no trial-specific follow-up visits conducted following randomization. Participant outcomes were collected from the Piedmont electronic health record (EHR) at 6, 12, 18, and 24 months after randomization.

Ethics Approval

Approvals for the trial were obtained by the Duke University institutional review board (2017-0738/D0479) and the Piedmont board in 2016. Verbal informed consent was provided from all participants prior to enrolling in the trial. The trial was registered on ClinicalTrials.gov (NCT03003403) on December 16, 2016. All data presented in this manuscript are deidentified. As Balance was a pragmatic trial with outcomes extracted from the Piedmont EHR and thus did not require participant study visits or follow-up surveys for evaluation, monetary compensation was not provided.

Study Setting and Sample

Congruent with the trial’s pragmatic design, we sought to limit eligibility criteria to those that were fundamental to intervention implementation or evaluation or represented a significant threat to patient safety. To be included, participants needed to be fluent in English or Spanish and have a BMI between 25 and 40 kg/m2 (inclusive) and a weight of 380 pounds or less, as recorded by a provider in the Piedmont EHR within the previous 14 days. The weight eligibility criterion was based on the weight capacity of the connected scales used for intervention delivery. Participants also needed a mobile phone and service plan that could receive weekly trial-related text messages. Exclusion criteria included pregnancy within 12 months, giving birth within 6 months, or breastfeeding within 2 months; having prior weight loss or bariatric surgery; or planning to relocate outside the Piedmont service area during the trial period.

Trial Recruitment, Screening, and Randomization

Trial recruitment launched in February 2017. In-person recruitment was conducted through a joint effort by Piedmont staff and a Balance research staff member, with Piedmont staff identifying possibly eligible participants and referring them to research staff for questions and additional information. Due to slower-than-expected study recruitment, 4 months into the trial, a new recruitment method was added: an EHR query was used to identify patients who met basic criteria (eg, age and BMI) for Balance and had an upcoming appointment at Piedmont. These patients identified via the EHR query were mailed materials ahead of their appointments and presented trial information during visits to the CHC, if a research team member was present at their appointment time. Interested patients from either recruitment method were prompted to sign an authorization form to allow research staff to assess their medical record for eligibility—and later for evaluation purposes, if enrolled. Following completion of the authorization form, patients underwent additional phone screening to assess criteria not available in their medical records, such as willingness to receive text messages. After eligibility was established, research staff continued to conduct verbal informed consent, enrollment, randomization, and program orientation procedures. Additional details regarding recruitment and screening procedures were previously described [14,15]. Randomization took place concurrently with enrollment between February 2017 and December 2018 using block randomization with stratification by the patient’s CHC within Piedmont Health, with equal allocation to each treatment group.

Healthy Living Usual Care Arm

Participants randomly assigned to the healthy living usual care arm received enhanced usual care. They received their standard primary care at Piedmont as well as 6 months of automated weekly text messages with healthy living information and printed materials adapted from the National Heart, Lung, and Blood Institute’s Aim for a Healthy Weight [16].

Balance Weight Gain Prevention Arm

The goal of the Balance intervention was to prevent weight gain by encouraging behavioral changes that result in a slight energy deficit. Intervention participants received (1) tailored behavior change goals, (2) skills training materials and videos, (3) weekly self-monitoring prompts for behavioral goal tracking, (4) connected scales for weight self-monitoring, and (5) responsive health and weight coaching from trained registered dietitians.

Behavioral goals were individually assigned and tailored to participants using the interactive obesity treatment approach. The processes for interactive obesity treatment approach goal assignment for Balance have been described elsewhere [14] and have been used in previous primary care obesity treatment trials [13,17,18]. Briefly, participants were administered a simple survey at the start of the trial with a built-in algorithm that creates a net caloric deficit on the backend. For example, participants were asked to rate the frequency of consuming sugary drinks or walking 10,000 steps per day and their perceived confidence to change this behavior. Based on the results of the frequency of each health behavior and their self-efficacy to change it, participants received a set of 3 goals which changed every 8 weeks. They monitored their goal progress by responding to weekly interactive voice response calls and text messages. Participants then received automated, tailored feedback that described their progress, reinforced successes, and offered motivational strategies or short skills training tips.

Throughout the intervention, participants were also asked to weigh themselves daily on a connected scale, as previously described [14,19,20]. Data were transmitted through cellular networks to a database accessible to the research team. A rolling 7-day average of these weights was used to activate the responsive coaching from a Balance dietitian when a participant reached a designated threshold, or zone, of weight gain. If no weights were received across 1 intervention week, study staff would attempt to contact the participant via text or phone to re-engage or troubleshoot.

Data Collection

Data collection procedures were designed to maximize the use of data collected during routine primary care [21]. Participant sociodemographic characteristics were collected by a brief survey administered as part of the enrollment phone call. All other participant baseline and follow-up data were pulled directly from the EHR (GE Centricity CPS, version 12). Weight measurements in the EHR were recorded in pounds to the nearest 0.1 pound and converted to kilograms for analysis. Height was recorded in inches to the nearest 0.01 inch and converted to centimeters for analysis. BMI was recorded as weight/height (kg/m2). EHR data were obtained on all participants between August 6, 2015, and April 30, 2021, including up to 18 months before enrollment through 30.5 months after enrollment.

For participants who became pregnant during the study, all clinical values were censored as of the beginning of their pregnancy. For pregnancies that occurred before enrollment, we censored clinical values from the beginning of pregnancy to 6 months after the end of pregnancy.

Statistical Methods

Baseline variables were summarized by the intervention arm as means and SDs for continuous variables and as counts and percentages for categorical variables. We used a 2-stage modeling strategy to answer our primary hypothesis. All analyses were intent-to-treat. For the first stage, we estimated the intervention effect on weight using a constrained longitudinal linear mixed-effects model [22], using all available data from between 18 months before enrollment through 30.5 months after enrollment. We explored nonlinearities for the fixed effects of time and random effects of time in the models, guided by the Bayesian information criterion and likelihood ratio tests. The model included fixed effects for time and interactions between time segments and intervention, with a random intercept and random slopes for time. The covariance between random effects was modeled using an unstructured covariance matrix. Randomization was stratified by CHC; thus, we adjusted for CHC in the analyses but did not adjust for other variables. Using this linear mixed-effects model, we estimated mean weight change by intervention arm, and the difference between intervention arms in mean weight change, at 6, 12, 18, and 24 months.

Second, we compared the percentage of ≤3% weight gain—our primary outcome—in each arm at 24 months after randomization using individual empirical best linear unbiased predictors (EBLUPs) from the mixed model [23]. To ensure good predictions, we only used individual EBLUPs from participants with at least 1 EHR weight documented within a 6-month window centered on the 24-month time point (ie, between 21 and 27 months after enrollment). We compared the percentage of ≤3% weight gain in intervention and usual care arms using both a log-binomial model and linear risk model on the EBLUP output, in order to obtain both risk ratios and risk differences, which provide estimates of relative and absolute efficacy, respectively [24]. The extra variability induced by the EBLUPs being predicted from the model was taken into account using a resampling procedure, explained further in the Multimedia Appendices 1 and 2. Sensitivity to the 21- to 27-month window was assessed by obtaining predictions after expanding the window. We additionally used EBLUPs to compare the percentage of ≤3% weight gain in each arm at 6, 12, and 18 months after randomization.

Additional sensitivity analyses included adjusting the model for baseline variables imbalanced across arms, by weight measured in the primary time window (P<.10) and removing telehealth visits from the analysis. We also explored effect modification by adding interactions to the primary model with age tertiles; gender; BMI class; race and ethnicity; and preferred language (English or Spanish), each in a separate model. Additionally, in post hoc analyses we added the completion date of the study (before or after COVID-19) as an effect modifier to examine the potential impact of COVID-19 on the intervention effect.


We randomized 443 participants, of which 223 (50.3%) participants were allocated to the intervention arm and 220 (49.7%) to the usual care arm. Participant demographics are summarized by intervention arm (Table 1). At baseline, participants had a mean BMI of 32.6 (SD 4.0) kg/m2 and most participants were Latino or Hispanic (200/443, 45.1%) or non–Latino or Hispanic White (115/443, 26%).

Table 1. Balance baseline demographics.
CharacteristicsControl (n=220)Intervention (n=223)Total (N=443)
Estimated baseline weight (in kg)a, mean (SD)86.8 (14.3)85.2 (13.1)86.0 (13.7)
Age (y), mean (SD)46.8 (13.0)48.5 (13.6)47.6 (13.3)
BMI value (kg/m2; EHRb), mean (SD)32.9 (3.9)32.4 (4.0)32.6 (4.0)
BMI class (kg/m2; EHR), n (%)

25 to <30: Overweight58 (26.4)70 (31.4)128 (28.9)

30 to <35: Class I obese97 (44.1)87 (39)184 (41.5)

35 to <40: Class II obese57 (25.9)64 (28.7)121 (27.3)

40+: Class III obese8 (3.6)2 (0.9)10 (2.3)
Hours of sleep per 24 hours, mean (SD)7.1 (1.4)6.7 (1.3)6.9 (1.3)
Patient Health Questionnaire-2 score, mean (SD)0.9 (1.2)1.0 (1.3)1.0 (1.3)
Sex, n (%)

Male46 (20.9)43 (19.3)89 (20.1)

Female173 (78.6)179 (80.3)352 (79.5)

Male to female transgender1 (0.5)1 (0.4)2 (0.5)
Race or ethnicity, n (%)

Hispanic (all races)98 (44.5)102 (45.7)200 (45.1)

Non-Hispanic Black53 (24.1)53 (23.8)106 (23.9)

Non-Hispanic other or unreported15 (6.8)7 (3.1)22 (5)

Non-Hispanic White54 (24.5)61 (27.4)115 (26)
Preferred language, n (%)

English145 (65.9)141 (63.2)286 (64.6)

Spanish75 (34.1)82 (36.8)157 (35.4)
Education, n (%)

Less than high school education37 (16.8)45 (20.2)82 (18.5)

High school graduate65 (29.5)84 (37.7)149 (33.6)

Some college, vocational degree, or associate’s degree88 (40)68 (30.5)156 (35.2)

College graduate or beyond30 (13.6)26 (11.7)56 (12.6)
Community health center, n (%)

Carrboro111 (50.5)113 (50.7)224 (50.6)

Chapel Hill28 (12.7)27 (12.1)55 (12.4)

Moncure66 (30)67 (30)133 (30)

Prospect Hill10 (4.5)11 (4.9)21 (4.7)

Siler City5 (2.3)5 (2.2)10 (2.3)
Recruitment method, n (%)

Via on site efforts only123 (55.9)127 (57)250 (56.4)

On site after mailing43 (19.5)42 (18.8)85 (19.2)

Via mail or off-site efforts only54 (24.5)54 (24.2)108 (24.4)
Leisure-time physical activity, n (%)

Refused2 (0.9)0 (0)2 (0.5)

Do not know or not sure2 (0.9)1 (0.4)3 (0.7)

No91 (41.4)86 (38.6)177 (40)

Yes125 (56.8)136 (61)261 (58.9)

aEstimated from primary linear mixed-effects model.

bEHR: electronic health record.

Among our sample, 53% (n=235) of participants had at least 1 visit with weight measured within the primary time window (21 to 27 months; see Figure 1). Participants with visits with weights measured dropped off dramatically during the COVID-19 pandemic (281/443, 63% in April-September 2019 vs 94/443, 21% in April-September 2020; 214/443, 48% in October 2019-February 2020 vs 50/443, 11% in October 2020-February 2021; see Table S1 in Multimedia Appendix 1). This reduced the number of visits in the primary outcome time window since 50% (n=220) of participants had not yet completed all 27 months of follow-up by the start of the pandemic (March 15, 2020). However, there was no significant difference between the arms in the numbers of visits with weights measured in the 21- to 27-month window (119/220, 54% in control vs 116/220, 52% in intervention with a weight measurement in this window; see Table S2 in Multimedia Appendix 1).

Figure 1. Balance CONSORT (Consolidated Standards of Reporting Trials) flow diagram. For a higher-resolution version of this figure, see Multimedia Appendix 3.

The linear spline model with knots at 6 months before enrollment; enrollment; and 6, 12, and 18 months after enrollment had the lowest Bayesian information criterion. Compared with the usual care arm, the intervention arm had greater mean weight change at 6 months (–1.2, 95% CI –2.1 to –0.2 kg); however, this estimate was attenuated by 24-months (–0.1, 95% CI –1.2 to 1.0 kg; see Figure 2). The intervention arm had a higher proportion with ≤3% weight gain at 6 months (risk ratio=1.12, 95% CI 0.94-1.28; risk difference=9.5, 95% CI –4.5 to 16.4 percentage points), which also attenuated to the null by 24 months (risk ratio=1.00, 95% CI 0.82-1.20; risk difference=0.2, 95% CI –12.1 to 11.0 percentage points; see Figure 3). Changing the window size around the 24-month time point did not appreciably affect these results (see Figures S1 and S2 in Multimedia Appendix 1). Further descriptive statistics regarding ≤3% weight gain are presented in Table S3 in Multimedia Appendix 1.

Figure 2. Predicted mean weight change (in kilograms) from baseline in intervention and control separately (panel A), and difference in weight change after baseline comparing intervention to control (panel B). Predictions are from the linear mixed-effects model. In panel B, negative values indicate that the intervention group lost more (or gained less) weight on average than the control group.
Figure 3. Risk ratio (panel A) and risk difference (panel B) comparing intervention and control on ≤3% weight gain. In panel A, values above 1 indicate that the intervention group had a greater relative probability of ≤3% weight gain versus control. In panel A, values above 0 indicate that the intervention group had a greater absolute probability of ≤3% weight gain versus control.

Weight measurements were collected at 75 total telehealth visits during the pandemic. After we removed telehealth visits from the model, there were no significant changes to the effect estimates. However, at 18 and 24 months, the effect attenuated toward the null (see Figure S3 in Multimedia Appendix 1).

Table S4 in Multimedia Appendix 1 displays baseline demographics for those with weight measured in the 21- to 27-month window. No variables were imbalanced between those with weight measured in this window versus those without weight measured in this window (P<.10); thus, no additional analyses were performed.

Figures S4-S7 in Multimedia Appendix 1 display the results of effect modification analysis. At 6 months, there is evidence of a stronger intervention effect in the 44-57 years age range relative to the ≤43 years age range. No other subgroups across time were significantly different with respect to the intervention effect, including post hoc subgroups based on 24-month completion relative to COVID-19 pandemic onset.


Principal Findings

We and others have demonstrated the efficacy of weight gain prevention interventions in adults affected by obesity [13,25]. However, in Balance, we did not find long-term evidence to support the dissemination of a digital weight gain prevention intervention to patients receiving primary care at CHCs. Compared with the usual care arm, the intervention arm experienced greater weight loss at 6 months, yet this difference was not clinically meaningful and had attenuated by 24 months. Further, we did not observe a difference between the 2 arms in the proportion of individuals who stayed within 3% of their baseline weight.

Comparison to Previous Work

Unlike our previous trials using similar approaches resulting in significant weight gain prevention or weight loss [13,18], Balance was designed to use a high level of pragmatism to deliver and evaluate real-world intervention effectiveness. This aligned with the key domains of the Pragmatic-Explanatory Continuum Indicator Summary index, including limited exclusion criteria, nonrestrictive control group, no formal follow-up data collection, and extraction of outcome data directly from the EHR [21]. Pragmatic trial designs vary considerably in the aforementioned domains and these characteristics can assist with contextualizing study findings. For instance, we did not restrict the usual care arm in this trial. As a result, some of these patients may have received medical nutrition therapy or other weight management services from Piedmont registered dietitians or community partners. These efforts may have resulted in the usual care arm experiencing better weight outcomes than expected among a restricted control group, ultimately diminishing trial outcomes.

As described in the methods section and more thoroughly in our protocol paper, the Balance study had a responsive weight and goal coaching protocol. There were 3 zones a participant would be categorized in, depending on their weight change, in which they may have received minimal to no coaching. This differs from our previous weight gain prevention trial that successfully prevented weight gain, in which participants received a standardized coaching protocol that included 20-minute monthly phone calls for 12 months, regardless of weight status [12,13]. It is possible that participants of the Balance intervention would have benefited from this standardized coaching protocol or a higher-intensity intervention.

To our knowledge, no examples exist of other pragmatic weight gain prevention trials in primary care settings among medically vulnerable populations with which to compare our findings. However, there have been several pragmatic weight loss trials implemented in the primary care setting. For example, the PROPEL and REPOWER trials were large, pragmatic randomized weight loss trials implemented in primary care clinics working with medically vulnerable populations and tested a total of 5 weight loss interventions with varying levels of pragmatism [26]. Both trials’ intervention arms observed significant weight loss at 6-months. Yet, not all intervention arms were as successful at producing weight loss, and notably, the arm designed with the highest level of pragmatism observed the least sustained weight loss at 24 months. Along with our study, these findings highlight the challenges of long-term weight management, particularly in pragmatic trials. Future studies might benefit from including additional support for changing motivation, group support, and targeted problem-solving strategies [27,28] to overcome external challenges.

Limitations and Considerations for Future Research

This study had limitations that should be noted. A potential challenge facing pragmatic weight management trials is the quality of clinic-measured weights. We previously assessed concordance between EHR and research-collected weight data in our earlier weight management interventions and did not find differences in baseline weight, changes in weight from baseline, or differences between intervention and controls in weight change [29]. However, estimates based on EHR weights were generally more variable than weights directly collected by the study team. Another more recent trial demonstrated that weight loss differences observed at 24 months were smaller when using EHR data [30]. The authors offered several explanations for this finding, including the larger variability in follow-up time and the less restrictive procedures for in-clinic weight measurement, such as those observed in Balance. Because we did not collect a secondary measure of weight, we are unable to assess if more controlled weight measurement procedures would have improved our ability to detect differences in weight gain between groups.

We expect that the timeframe of implementation posed challenges to identifying the effects of the Balance intervention on weight outcomes. Namely, the COVID-19 pandemic began during the implementation of the Balance intervention and our 24-month follow-up period. This decreased the number of in-person visits being conducted at the CHCs and, ultimately, impacted follow-up data collection on nearly half of our participants. COVID-19 could have also impacted other weight-related behaviors and risk factors among participants, including physical activity [31,32], food access and dietary quality [33-35], and mental health stressors [36,37]. In addition to COVID-19, there were several other events during the intervention and follow-up timeframe that could have impacted data collection, including 2 major North Carolina hurricanes and immigration reform resulting in increased deportation of undocumented individuals. These factors likely impacted patient appointment attendance and thus the availability of baseline and follow-up EHR data. As such, these events may have affected the precision of the intervention effect estimates for outcomes at 24 months. However, it is unlikely the intervention effect estimates themselves were biased by these events, as there was no difference between the number of visits with weights measured by treatment arms.

Additionally, some components of trial implementation did not align with a pragmatic approach, such as using research staff to conduct recruitment at the health centers. There were also institutional requirements for research compliance that would not be necessary if implemented within a real-world setting. For instance, a Health Insurance Portability and Accountability Act (HIPAA) authorization form was required from each participant before screening could occur, which posed challenges to recruitment ease and timing, as highlighted in our previous article [15]. However, if Balance were disseminated further within Piedmont or other similar CHCs without the inclusion of external research partners, these specific requirements would likely have been lessened or eliminated, thereby decreasing the amount of time required to enroll in the program. Finally, as discussed above, several events, such as COVID-19, occurred during study implementation that impacted data collection. However, as described above, we expect this did not bias effect estimates.

Strengths

Despite these limitations, there are many notable strengths. The Balance trial was designed with a high level of pragmatism, with limited criteria for eligibility and no study-specific data collection or follow-up procedures, and enrolled a diverse sample of participants. For these reasons, the Balance trial also provides results that can inform decisions in real-world care settings for the management of obesity. Although the intervention did not have a significant impact on weight gain prevention, it is possible that participants adopted healthy dietary and physical activity behaviors that positively impact health and chronic disease management [38]; however, these outcomes were not assessed in this study. Future assessment is warranted given long-term healthy lifestyle changes are possible independent of weight change after participation in a weight gain prevention program [39].

To the best of our knowledge, Balance was also the first weight gain prevention trial to be implemented with a pragmatic design in a primary care setting serving a medically vulnerable population, serving as a strong example of successful partnerships between research teams and CHCs. This sentiment was echoed by Piedmont providers and staff in a qualitative evaluation of Balance [40], in which they stated that early buy-in from providers and staff, respect for the patients and health care setting by the research partnership, and filling a treatment gap for patients all contributed to successful trial implementation. Combined with the trial outcomes, these findings can be used to inform future programs and interventions to be tested and implemented in the CHC setting.

Conclusions

Balance did not exhibit a positive impact on long-term weight maintenance, yet it provides important information for future pragmatic trials in the primary care setting. Future trials might benefit from including an assessment of the comparator group’s engagement in weight management behaviors and collecting a secondary weight measurement. Researchers may also consider measuring other outcomes associated with chronic disease prevention that are independent of weight, such as changes in diet quality, physical activity, and psychological health.

Acknowledgments

This trial was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (R18DK109518). The funder had no role in study design, data collection, data analysis, and interpretation of data, in the writing of the report, and in the decision to submit this article for publication. The authors wish to express our deepest gratitude to the administration and staff at Piedmont Health for their continued collaboration and support. In particular, the authors would like to thank Brian Toomey, Jennifer Cunningham, Erica Boshnack, Kristen Norton, Caitlyn Faul, Harriett Burns, Tom Hadley, and all the providers and staff at the participating community health centers. The authors are also grateful to Dori Steinberg, Brian C Batch, and all other Duke staff and research assistants who provided project assistance. Last, the authors would like to especially thank the Piedmont Health patients who participated in Balance.

Conflicts of Interest

GGB is on the scientific advisory board for WeightWatchers and Wondr Health. EAF has past relationships with WeightWatchers, Jenny Craig, and several pharmaceutical companies in the obesity space but has no current industry relationships or financial interests in companies providing weight-loss products or services. All other authors have no conflicts of interest to declare.

Multimedia Appendix 1

Estimating variance for the empirical best linear unbiased predictions (EBLUPs).

PDF File (Adobe PDF File), 1700 KB

Multimedia Appendix 2

CONSORT E-HEALTH checklist.

PDF File (Adobe PDF File), 3511 KB

Multimedia Appendix 3

Balance CONSORT (Consolidated Standards of Reporting Trials) flow diagram.

PNG File , 326 KB

  1. Ard J. Obesity in the US: what is the best role for primary care? BMJ. 2015;350:g7846. [CrossRef] [Medline]
  2. Ogden CL, Carroll MD, Flegal KM. Prevalence of obesity in the United States. JAMA. 2014;312(2):189-190. [CrossRef] [Medline]
  3. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491-497. [FREE Full text] [CrossRef] [Medline]
  4. Yang L, Colditz GA. Prevalence of overweight and obesity in the United States, 2007-2012. JAMA Intern Med. 2015;175(8):1412-1413. [FREE Full text] [CrossRef] [Medline]
  5. Ogden CL, Lamb MM, Carroll MD, Flegal KM. Obesity and socioeconomic status in adults: United States, 2005-2008. NCHS Data Brief. 2010;(50):1-8. [FREE Full text] [Medline]
  6. Chow EA, Foster H, Gonzalez V, McIver L. The disparate impact of diabetes on racial/ethnic minority populations. Clin Diabetes. 2012;30(3):130-133. [FREE Full text] [CrossRef]
  7. Rodriguez F, Ferdinand KC. Hypertension in minority populations: new guidelines and emerging concepts. Adv Chronic Kidney Dis. 2015;22(2):145-153. [FREE Full text] [CrossRef] [Medline]
  8. Befort CA, Nazir N, Perri MG. Prevalence of obesity among adults from rural and urban areas of the United States: findings from NHANES (2005-2008). J Rural Health. 2012;28(4):392-397. [FREE Full text] [CrossRef] [Medline]
  9. Osei-Assibey G, Kyrou I, Adi Y, Kumar S, Matyka K. Dietary and lifestyle interventions for weight management in adults from minority ethnic/non-white groups: a systematic review. Obes Rev. 2010;11(11):769-776. [CrossRef] [Medline]
  10. Yancey AK, Kumanyika SK, Ponce NA, McCarthy WJ, Fielding JE, Leslie JP, et al. Population-based interventions engaging communities of color in healthy eating and active living: a review. Prev Chronic Dis. 2004;1(1):A09. [FREE Full text] [Medline]
  11. Wadden TA, Butryn ML, Hong PS, Tsai AG. Behavioral treatment of obesity in patients encountered in primary care settings: a systematic review. JAMA. 2014;312(17):1779-1791. [FREE Full text] [CrossRef] [Medline]
  12. Foley P, Levine E, Askew S, Puleo E, Whiteley J, Batch B, et al. Weight gain prevention among Black women in the rural community health center setting: the shape program. BMC Public Health. 2012;12:305. [FREE Full text] [CrossRef] [Medline]
  13. Bennett GG, Foley P, Levine E, Whiteley J, Askew S, Steinberg DM, et al. Behavioral treatment for weight gain prevention among Black women in primary care practice: a randomized clinical trial. JAMA Intern Med. 2013;173(19):1770-1777. [FREE Full text] [CrossRef] [Medline]
  14. Berger MB, Steinberg DM, Askew S, Gallis JA, Treadway CC, Egger JR, et al. The balance protocol: a pragmatic weight gain prevention randomized controlled trial for medically vulnerable patients within primary care. BMC Public Health. 2019;19(1):596. [FREE Full text] [CrossRef] [Medline]
  15. Miller HN, Berger MB, Askew S, Kay MC, Chisholm M, Sirdeshmukh G, et al. Recruitment of diverse community health center patients in a pragmatic weight gain prevention trial. J Clin Transl Sci. 2023;7(1):e22. [FREE Full text] [CrossRef] [Medline]
  16. Aim for a healthy weight. NIH 05-5213. National Institutes of Health. 2005. URL: https://www.nhlbi.nih.gov/resources/aim-healthy-weight-patient-booklet [accessed 2024-03-05]
  17. Bennett GG, Warner ET, Glasgow RE, Askew S, Goldman J, Ritzwoller DP, et al. Obesity treatment for socioeconomically disadvantaged patients in primary care practice. Arch Intern Med. 2012;172(7):565-574. [FREE Full text] [CrossRef] [Medline]
  18. Bennett GG, Steinberg D, Askew S, Levine E, Foley P, Batch BC, et al. Effectiveness of an app and provider counseling for obesity treatment in primary care. Am J Prev Med. 2018;55(6):777-786. [FREE Full text] [CrossRef] [Medline]
  19. Foley P, Steinberg D, Levine E, Askew S, Batch BC, Puleo EM, et al. Track: a randomized controlled trial of a digital health obesity treatment intervention for medically vulnerable primary care patients. Contemp Clin Trials. 2016;48:12-20. [FREE Full text] [CrossRef] [Medline]
  20. Steinberg DM, Tate DF, Bennett GG, Ennett S, Samuel-Hodge C, Ward DS. The efficacy of a daily self-weighing weight loss intervention using smart scales and e-mail. Obesity (Silver Spring). 2013;21(9):1789-1797. [FREE Full text] [CrossRef] [Medline]
  21. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A Pragmatic-Explanatory Continuum Indicator Summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62(5):464-475. [FREE Full text] [CrossRef] [Medline]
  22. Lu K. On efficiency of constrained longitudinal data analysis versus longitudinal analysis of covariance. Biometrics. 2010;66(3):891-896. [FREE Full text] [CrossRef] [Medline]
  23. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis, 2nd Edition. Hoboken, NJ. John Wiley & Sons; 2012.
  24. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):e1-e37. [FREE Full text] [CrossRef] [Medline]
  25. Martin JC, Awoke MA, Misso ML, Moran LJ, Harrison CL. Preventing weight gain in adults: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2021;22(10):e13280. [CrossRef] [Medline]
  26. Katzmarzyk PT, Apolzan JW, Gajewski B, Johnson WD, Martin CK, Newton RL, et al. Weight loss in primary care: a pooled analysis of two pragmatic cluster-randomized trials. Obesity (Silver Spring). 2021;29(12):2044-2054. [FREE Full text] [CrossRef] [Medline]
  27. Greaves C, Poltawski L, Garside R, Briscoe S. Understanding the challenge of weight loss maintenance: a systematic review and synthesis of qualitative research on weight loss maintenance. Health Psychol Rev. 2017;11(2):145-163. [FREE Full text] [CrossRef] [Medline]
  28. Spreckley M, Seidell J, Halberstadt J. Perspectives into the experience of successful, substantial long-term weight-loss maintenance: a systematic review. Int J Qual Stud Health Well-being. 2021;16(1):1862481. [FREE Full text] [CrossRef] [Medline]
  29. Gallis JA, Kusibab K, Egger JR, Olsen MK, Askew S, Steinberg DM, et al. Can electronic health records validly estimate the effects of health system interventions aimed at controlling body weight? Obesity (Silver Spring). 2020;28(11):2107-2115. [FREE Full text] [CrossRef] [Medline]
  30. Katzmarzyk PT, Mire EF, Martin CK, Newton RL, Apolzan JW, Price-Haywood EG, et al. Comparison of weight loss data collected by research technicians versus electronic medical records: the PROPEL trial. Int J Obes (Lond). 2022;46(8):1456-1462. [FREE Full text] [CrossRef] [Medline]
  31. Park AH, Zhong S, Yang H, Jeong J, Lee C. Impact of COVID-19 on physical activity: a rapid review. J Glob Health. 2022;12:05003. [FREE Full text] [CrossRef] [Medline]
  32. Harrison E, Monroe-Lord L, Carson AD, Jean-Baptiste AM, Phoenix J, Jackson P, et al. COVID-19 pandemic-related changes in wellness behavior among older Americans. BMC Public Health. 2021;21(1):755. [FREE Full text] [CrossRef] [Medline]
  33. Picchioni F, Goulao LF, Roberfroid D. The impact of COVID-19 on diet quality, food security and nutrition in low and middle income countries: a systematic review of the evidence. Clin Nutr. 2022;41(12):2955-2964. [FREE Full text] [CrossRef] [Medline]
  34. Lee MM, Poole MK, Zack RM, Fiechtner L, Rimm EB, Kenney EL. Food insecurity and the role of food assistance programs in supporting diet quality during the COVID-19 pandemic in Massachusetts. Front Nutr. 2022;9:1007177. [FREE Full text] [CrossRef] [Medline]
  35. Kent K, Alston L, Murray S, Honeychurch B, Visentin D. The impact of the COVID-19 pandemic on rural food security in high income countries: a systematic literature review. Int J Environ Res Public Health. 2022;19(6):3235. [FREE Full text] [CrossRef] [Medline]
  36. Xiong J, Lipsitz O, Nasri F, Lui LMW, Gill H, Phan L, et al. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020;277:55-64. [FREE Full text] [CrossRef] [Medline]
  37. Mental health and COVID-19: early evidence of the pandemic’s impact: scientific brief, 2 march 2022. World Health Organization. 2022. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Mental_health-2022.1 [accessed 2024-03-05]
  38. Gaesser GA, Angadi SS, Sawyer BJ. Exercise and diet, independent of weight loss, improve cardiometabolic risk profile in overweight and obese individuals. Phys Sportsmed. 2011;39(2):87-97. [CrossRef] [Medline]
  39. Driehuis F, Barte JCM, Ter Bogt NCW, Beltman FW, Smit AJ, van der Meer K, et al. Maintenance of lifestyle changes: 3-year results of the Groningen overweight and lifestyle study. Patient Educ Couns. 2012;88(2):249-255. [FREE Full text] [CrossRef] [Medline]
  40. Berger MB, Chisholm M, Miller HN, Askew S, Kay MC, Bennett GG. "We bleed for our community:" a qualitative exploration of the implementation of a pragmatic weight gain prevention trial from the perspectives of community health center professionals. BMC Public Health. 2023;23(1):695. [FREE Full text] [CrossRef] [Medline]


CHC: community health center
EBLUP: empirical best linear unbiased predictor
EHR: electronic health record
HIPAA: Health Insurance Portability and Accountability Act


Edited by G Greco; submitted 17.07.23; peer-reviewed by R Newton, A Bucher; comments to author 07.12.23; revised version received 07.02.24; accepted 26.02.24; published 28.03.24.

Copyright

©Hailey N Miller, John A Gallis, Miriam B Berger, Sandy Askew, Joseph R Egger, Melissa C Kay, Eric Andrew Finkelstein, Mia de Leon, Abigail DeVries, Ashley Brewer, Marni Gwyther Holder, Gary G Bennett. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 28.03.2024.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.